

TECHNOLOGY
Utilizing a newly discovered anti-cancer defense mechanism for cancer therapy

At the heart of AnserBio’s technology are two groundbreaking innovations

Harnessing a natural anti-cancer defense mechanism unique to specific tissues

A unique, patented nanoparticle-based
delivery system
By transforming this natural, localized defense system into a novel, first-in-class systemic cancer treatment, we are reshaping the future of oncology.
Biomimicking: cancer protection inspired by evolution
p53
p53
p53
p53
DNA





Drawing inspiration from nature’s defense strategies, AnserBio harnesses the remarkable potential of exosomes to deliver a unique complex of tumor-suppressor proteins, including functional p53, directly into cancer cells.

Known as the 'guardian of the genome,' the p53 protein suppresses mutations and maintains DNA integrity. When p53 is mutated, cells lose this essential defense mechanism. p53 mutations are common in cancer and often correlate with poor clinical outcomes. The most aggressive cancers, including glioblastoma (GBM), colon, ovarian, bladder, and lung cancers, are characterized by a high prevalence of p53 mutations.

AnserBio’s innovative technology is based on a natural anti-cancer defense system discovered in the cornea, which rarely develops cancer despite constant UV exposure. This is due to the cornea’s ability to transfer healthy p53 proteins between cells via exosomes, nano-vesicles produced by corneal cells containing high concentrations of p53.
Exosomes are nanoparticle-sized vesicles that mediate cell-to-cell communication by
transporting bioactive molecules. In cancer, they regulate key processes like angiogenesis, immune response, and metastasis.
Inspired by this protective mechanism, AnserBio developed technology to produce
p53-carrying vesicles from corneal cells.
These Cell-Derived Vesicles (CDVs) provide a safe, efficient delivery system for
cancer therapy.
p53 Replacement Therapy
First-in-class selective apoptotic and anti-angiogenic effect
In healthy cells, p53 exists as a functional tetramer, but in malignant cells, it becomes non-functional. Previous efforts to deliver healthy human p53 to cancer cells have failed due to a dominant-negative effect, where the mixed tetramer with mutated p53 remains non-functional.
AnserBio overcomes this challenge by utilizing non-human functional p53, which does not interact with human p53 in tetramer formation. This allows for the creation of fully functional tetramers that can effectively drive cancer cells into apoptosis.
The delivery of functional non-human p53 via CDVs triggers the rapid activation of p53-responsive genes, leading to apoptosis and the death of cancer cells.

Therapeutic CDVs produced through a scalable process
By harnessing the beneficial properties of exosomes and enhancing them with cutting-edge technological processes, AnserBio is pushing nanoparticle production to new heights of innovation.

Synergistic effect in combination
This innovative treatment can be used as a monotherapy or synergistically with conventional chemotherapy, radiotherapy, and emerging immunomodulatory therapies, enhancing treatment sensitivity. By doing so, it has the potential to reduce the toxicities and side effects commonly associated with these treatments.

Non-cytotoxic
The vesicles effectively deliver their therapeutic cargo throughout the body and can readily cross the blood-brain barrier. Additionally, our approach is non-cytotoxic and has shown no adverse immune responses, minimizing the risk of side effects.

Off-the-shelf
The process supports both injectable and intranasal off-the-shelf formulations

At the forefront of research & innovation


Compelling preclinical results
AnserBio has successfully delivered the p53 protein into various cancer cell types, leading to significant tumor growth suppression. Experimental results reveal rapid and substantial apoptosis within 24 hours of exposure in brain, colon, ovarian, and lung cancer cell lines. These outcomes translate 40 years of theoretical research into a tangible medical breakthrough, marking a significant advancement in cancer treatment.